Project Grant R43GM151897
- Federal Grant Award Summary Electronic Biosciences, Inc. received a $418,854 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), awarded June 8, 2026, with completion targeted for May 31, 2028. The award supports the development of a next-generation single-molecule protein sequencing platform designed to advance oncoproteomic research. The platform will leverage nanopore sequencing strategies to directly sequence individual protein molecules,...
- This $420,000 Project Grant, awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), funds fundamental research to advance proximity labeling techniques for protein and lipid analysis. Awarded to Yale University on July 1, 2026, with completion targeted for February 28, 2031, the project delivers engineered enzymes, novel chemical probes, and optimized methodologies designed to overcome current limitations...
- Federal Project Grant Award Summary Proteovista LLC received a $306,151 project grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded June 2, 2026, with completion targeted for May 31, 2027. The grant funds development of ClusterBuild, a novel synthetic biology platform designed to enable cost-effective, high-fidelity synthesis of large biosynthetic gene clusters (BGCs) up to 100 kilobases. The...
- This federal Project Grant award of $349,566 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of a Spotting-Free Nano-Oscillator Array (SFNOA) technology for high-throughput, label-free quantification of ligand binding kinetics to transmembrane proteins in their native states. The key products and services delivered through this award include: Integration of innovative technologies...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded Rybodyn, Inc. a $306,700 Project Grant effective September 15, 2025, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a novel spatial biology platform for protein profiling. The company will create a scalable, cost-effective, image-free spatial proteomics system that achieves subcellular resolution using proprietary barcoded tags and an isothermal workflow....
- This two-year, $600,000 Project Grant from the National Science Foundation's Biological Sciences program (CFDA 47.074) will support the development of a new antibody and sequencing-based strategy to comprehensively map and monitor dynamic protein interaction networks at high-throughput and single complex resolution. Specifically, the grantee, Columbia University, aims to barcode antibodies to uniquely identify up to hundreds of target proteins and employ a combinatorial barcoding split-pool...
- This Project Grant award from the National Science Foundation (NSF) under the Computer and Information Science and Engineering program (CFDA 47.070) provides $101,368 to North Carolina Agricultural and Technical State University (NC A&T) to develop new computational methods for de novo protein sequencing and filling gaps in protein scaffolds. The key products and services to be delivered include: Through a two-phase approach, the researchers will first analyze top-down and bottom-up mass...
- Micropure Genomics Inc. received a $274,199 Project Grant award from the National Science Foundation to advance methods for rapid, end-to-end sample preparation for sequencing applications. Under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the company will develop an automated process relying on electro-hydrodynamic trapping to isolate genomic material like DNA or RNA from cells in a flow cartridge. The process aims to significantly reduce preparation time while...
- Federal Grant Award Summary Potomac Affinity Proteins, LLC received a $377,602 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded July 1, 2026, with a completion date of June 30, 2027. The award funds development of a protease chain reaction (PROCR) technology designed to enable rapid, highly sensitive, and quantitative detection of biomolecules through simple mix-and-read assays. The...
- Federal Grant Award Summary Primary Bioscience, Inc. received a $305,000 Small Business Technology Transfer (STTR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) effective July 15, 2025, with a completion date of June 30, 2026. The company is developing an ultra-sensitive biosensor capable of single-molecule protein analysis and sequencing. The technology integrates a nanopatterned chip with a proprietary amino acid and...
SINGLE-MOLECULE PROTEIN SEQUENCING BY BARCODING OF N-TERMINAL AMINO ACIDS - SUMMARY PROTEINS ARE RESPONSIBLE FOR MUCH OF THE STRUCTURE AND FUNCTION OF ALL CELLS. SUBTLE CHANGES IN EXPRESSION OF VAR- IOUS PROTEIN FORMS ARE CRITICAL FOR PROPER GROWTH AND DEVELOPMENT, BUT IRREGULARITIES CAN CAUSE DELETERIOUS CELLULAR EFFECTS OR LARGE-SCALE BIOLOGICAL DYSFUNCTION. SEQUENCING SAMPLES WITH BOTH HIGH- AND LOW-ABUNDANCE PROTEINS COULD GREATLY ACCELERATE RESEARCH INTO PROTEIN FUNCTION AND BIOLOGY, BUT THERE IS CURRENTLY NO EFFICIENT AND COST-EFFECTIVE STRATEGY TO SEQUENCE MIXTURES OF UNKNOWN PROTEIN MOLECULES AT SINGLE-AMINO-ACID RESOLUTION. TWO METHODS ARE COMMERCIALLY AVAILABLE FOR PROTEIN SEQUENCING. THE FIRST METHOD, "EDMAN DEGRADATION", RE- QUIRES PURIFICATION OF THE INDIVIDUAL TARGET PROTEIN. BULK QUANTITIES OF WHOLE PROTEIN OR PURIFIED FRAGMENTS ARE SEQUENCED BY CLEAVING OFF THE FIRST (N-TERMINAL) AMINO ACID AND CHEMICALLY IDENTIFYING IT. THE SECOND METHOD, BASED ON MASS SPECTROMETRY, REQUIRES ENZYMATICALLY DEGRADING A SINGLE PROTEIN OR MIXTURE OF PROTEINS INTO SMALL FRAGMENTS, THEN ANALYZING THE MOLECULAR MASS AND CHARGE OF EACH FRAGMENT. THIS INFORMATION IS COM- PARED TO THAT OF KNOWN PROTEIN SEQUENCES TO INFER THE IDENTITY OF THE INPUT PROTEINS. BOTH OF THESE METHODS REQUIRE ~1 MILLION MOLECULES OF EACH PROTEIN FOR DETECTION. CURRENTLY, EDMAN DEGRADATION CANNOT BE USED ON HETEROGENEOUS PROTEIN MIXTURES, FURTHER LIMITING ITS UTILITY. SINGLE MOLECULE PROTEIN SEQUENCING IS HINDERED BY THE NUMBER AND DIVERSITY OF AMINO ACIDS, AS WELL AS THE IN- TERACTIONS BETWEEN AMINO ACIDS THAT INTERFERE WITH CHEMICAL IDENTIFICATION OF THEIR SIDE CHAINS. IDENTIFYING N- TERMINAL AMINO ACID THAT IS STILL ATTACHED TO THE REST OF THE PROTEIN WILL BE HINDERED BY THE N-1 (AND N-2) AMINO ACIDS, PROPORTIONAL TO THE BULK OF THE SIDE CHAIN. HARSH DENATURATION AGENTS CAN MITIGATE SOME OF THESE ISSUES. HOWEVER, THESE REAGENTS CAN COMPROMISE THE BIOMOLECULE-BASED IDENTIFICATION SYSTEMS THEMSELVES AND DO NOT FULLY REMOVE THE STERIC HINDRANCE, AFFECTING THE ACCESS TO THE N-TERMINAL AMINO ACID. GLYPHIC BIOTECHNOLOGIES HAS DEVELOPED A NOVEL "NEXT-GENERATION" PROTEIN SEQUENCING STRATEGY, IN WHICH DNA BARCODES ASSOCIATE ROUNDS OF CLEAVED N-TERMINAL AMINO ACID WITH A PROTEIN-SPECIFIC BARCODE. EACH OF THE 20 DIFFERENT AMINO ACIDS WILL BE FIRST CLEAVED (CIRCUMVENTING THE STEARIC HINDRANCE OF THE N-1 AMINO ACID) AND THEN CAPTURED BY SPECIFIC ANTIBODIES. EACH AMINO ACID WILL THEN BE ASSOCIATED WITH TWO BARCODES, INDICATING THE (1) ORIGINATING PROTEIN AND (2) SEQUENTIAL POSITION THIS AMINO ACID CAN BE FOUND IN. AFTER NEXT-GENERATION DNA SE- QUENCING OF ALL CONJUGATED BARCODES, THIS INFORMATION CAN BE DECONVOLUTED - PLACING EACH AMINO ACID INTO THE CORRECT POSITION WITHIN THE CORRECT PROTEIN. THIS APPROACH HAS THE POTENTIAL TO BE SCALED TO SEQUENCE MILLIONS TO BILLIONS OF SINGLE MOLECULES SIMULTANEOUSLY IN HOURS. DEVELOPING THIS TECHNOLOGY WILL REVOLUTIONIZE PROTEIN ANALYSIS BY MAKING LARGE-SCALE PROTEIN SEQUENC- ING FEASIBLE, INEXPENSIVE, AND ROUTINE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 2/28/25 | ||
| Not listed | $0 | 1/25/24 | ||
| Not listed | $0 | 1/25/24 | ||
| Not listed | $359.0k | 9/13/23 | ||
| Not listed | $359.0k | 9/13/23 |